GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System

GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System

Six key considerations to help you deliver optimal results.

Stent graft deployment

Unique angulation control

98% reported that the proximal wall apposition was acceptable at procedural completion1

Next: view procedural videos

   

Thumbnail of Hemodynamic Flow

Hemodynamic stability

NO rapid pacing used in 93% of cases1

   

   

why oversizing matters

Unique oversizing window

16-42mm Aortic Diameter Range as few as 5 sizes

Next: Download sizing guide

   

video thumbnail

Conformability

Real world2 treatment* transection zero Type III endoleaks†, ruptures, device fractures, compressions, conversions

  

 

Thumbnail image for Aortic Ally FSA Stories from the Field video

Support you can count on   

  • 8+ years  –  Average field representatives’ tenure supporting Gore’s aortic devices, building on diverse clinical backgrounds
  • Non-commissioned sales force – our focus is on outcomes
  • Training needs – Essential technical support with a deep reservoir of product knowledge
  • From pre-case planning to procedural consultation we are by your side to provide support

Contact your Gore representative:
Email MPDTempeSalesSupport@wlgore.com
Call 800-469-6999, or Request contact

Conformability Defined »

* GORE® TAG® Conformable Device.
† Endoleak requiring intervention. No endoleaks persisted past one month or required intervention.

  1. W. L. Gore & Associates.  Observational Registry Characterizing the Performance and Feature Use of the GORE® TAG® Conformable Thoracic Stent Graft Featuring ACTIVE CONTROL System.  NLM Identifier: NCT03286400.  Published September 18, 2017.  Updated December 17, 2020. Accessed February 23, 2021.   Available from: https://clinicaltrials.gov/ct2/show/NCT03286400
  2. GREAT is a prospective, observational, multicenter registry to actively track Gore commercial aortic endovascular device performance and associated patient outcomes in global markets with 10 years of follow-up. Data June 2017. Through 2-year follow-up. Transection n = 53.

22755804-EN